CagriSema (Cagrilintide + Semaglutide)
Also known as CagriSema · Cagri+Sema · Cagrilintide/Semaglutide combo
New
Reconstitution & dosing guide
5 mg · 10 mg · 20 mg vial sizes — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only20mg x 10 vials
Cagri+sema (10mg+10mg) · Not in current stock
$165 / vial
5mg x 10 vials
Cagri+sema (2.5mg+2.5mg) · Not in current stock
$55 / vial
10mg x 10 vials
Cagri+sema (5mg+5mg) · Not in current stock
$90 / vial
Prices per vial · Research use only · Not medical advice.
Fixed dual research blend combining amylin analog cagrilintide with GLP-1 agonist semaglutide — mirrors the highly effective investigational obesity combination approach.
How to picture it
Appetite and fullness are multi-channel. Semaglutide-style GLP-1 pathways slow the meal and quiet "keep eating" noise; cagrilintide-style amylin pathways reinforce satiety and gastric pacing from a different angle. Picture the "I'm done" signal arriving from two hormone systems at once — dual satiety architecture researched for larger effects than either message alone.
Research focus & benefits
- Dual GLP-1 + amylin satiety research
- Complementary gastric-emptying pathway studies
- Combination weight-management science
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
CagriSema refers to co-administration or co-formulated cagrilintide (long-acting amylin analog) plus semaglutide. Clinical development of the combination has shown weight-loss percentages among the highest in obesity medicine. Catalog vials supply both peptides in one research unit at several dose pairings (2.5+2.5, 5+5, 10+10 mg).
Mechanism
Semaglutide: GLP-1R agonism for appetite, gastric emptying, and glycemic control. Cagrilintide: amylin receptor agonism adding satiety, meal-size reduction, and complementary central appetite pathways. Together they hit multiple energy-balance nodes.
Research uses
- Phase 2/3 CagriSema obesity program readouts
- Amylin + GLP-1 combination pharmacology
- Comparison vs mono-agonist and dual GIP/GLP-1 agents
Research dosing notes
Clinical CagriSema uses careful weekly titration. Research blends are not licensed combo product — do not equate to trial drug.
Half-life / kinetics
Both components long-acting (days); weekly research framing
Common research routes
Reported considerations
- Additive GI side effects (nausea)
- Gallbladder risk class effects
- Muscle-loss with large weight drops
Contraindications / cautions
- Personal/family MTC or MEN2 (GLP-1 class warning)
- Pregnancy
- History of pancreatitis
Common research stacks
- Retatrutide (triple agonist alternative)
- Tirzepatide
- Cagrilintide solo
Legal / access note
Investigational combination concept with strong trial data for the pharmaceutical program. Research vials are not approved CagriSema drug product.